Although the physiological properties of the myocardium and their dynamic character have been the focus of intense research during the past three decades, the biochemical and molecular correlates underlying cardiac performance for the most part remain poorly understood. The central role of the myocardium in the maintenance of the cardiac output notwithstanding, until very recently the prevailing view of the heart was that of a biochemically very static organ. Therefore, it did not seem either particularly interesting or suitable to address major questions of cellular and molecular biology affecting normal and pathological states. As a consequence, the impact of the newly developed techniques of recombinant DNA and genetic manipulation in transgenic animals on the understanding of cardiac cellular and molecular biology has been less significant than on other fields of biomedical sciences. With few exceptions, the power of these new techniques and approaches is just beginning to be felt in the field of cardiovascular biology. This state of affairs is more surprising given the biomedical importance of the cardiovascular system in general and the myocardium in particular, as well as the large number of investigators dedicated to its study. This situation is due, at least in part, to the characteristics of the myocardium that, until recently, have made this organ a less than ideal model system for a molecular and genetic approach.
Although the physiological properties of the myocardium and their dynamic character have been the focus of intense research during the past three decades, the biochemical and molecular correlates underlying cardiac performance for the most part remain poorly understood. The central role of the myocardium in the maintenance of the cardiac output notwithstanding, until very recently the prevailing view of the heart was that of a biochemically very static organ. Therefore, it did not seem either particularly interesting or suitable to address major questions of cellular and molecular biology affecting normal and pathological states. As a consequence, the impact of the newly developed techniques of recombinant DNA and genetic manipulation in transgenic animals on the understanding of cardiac cellular and molecular biology has been less significant than on other fields of biomedical sciences. With few exceptions, the power of these new techniques and approaches is just beginning to be felt in the field of cardiovascular biology. This state of affairs is more surprising given the biomedical importance of the cardiovascular system in general and the myocardium in particular, as well as the large number of investigators dedicated to its study. This situation is due, at least in part, to the characteristics of the myocardium that, until recently, have made this organ a less than ideal model system for a molecular and genetic approach.
Due to the essential role ofthe myocardium in the survival of the organism, most of the genetic mutations that significantly affect its development and/or function are likely to be lethal. This feature explains the very small number of mutations described so far affecting the myocardium either in human or animal models. This is in contrast with the large number of mutations affecting blood cells, the endocrine system, and metabolic pathways, among others. The existence of these mutations has provided the port of entry for the molecular dissection ofthese systems. In addition to the unavailability of mutations, the difficulty in obtaining repeated samples of the myocardium that are suitable for biochemical and molecular analysis from the same animal has also slowed progress. Furthermore, the existence of well-characterized cell lines that can be grown in homogeneous populations and mutated at will are an almost essential requirement for the exploitation of recombinant DNA technology to elucidate regulatory pathways. Given that the cardiac myocyte is a terminally differentiated cell that has lost its ability to replicate in vivo or in vitro shortly after birth (1) , no cell lines with well-defined characteristics of cardiac myocytes have been available until now. This combination of characteristics, broadly outlined above, has played an important role in delaying the dissection of the cellular and molecular basis of cardiac performance in physiological and pathological states. Yet it is clear that the application of the modem techniques of cellular and molecular biology holds great promise to elucidate some of the major problems in clinical and experimental cardiovascular medicine. In addition, it is becoming increasingly clear that the cardiovascular system in general and the myocardium in particular are excellent model systems to address not only particular cardiovascular problems but also some broad biological questions that have general significance and are of import to a large number of organs and systems.
It is our objective to review summarily some of the recent advances in the understanding of the biology of the myocardium and its response to physiological and pathological stimuli. Particular emphasis will be placed on the contractile apparatus and on those areas that highlight the extraordinary plasticity of this tissue at the biochemical level and appear particularly suitable for a molecular approach.
The cardiac contractile apparatus The unit of contraction in the myocardium, as well as in the skeletal muscle, is the sarcomere (2) . The contractile properties of the myocardium, both in terms of force generated and velocity of contraction, are dependent on the number as well as the biochemical composition of its sarcomeres. The sarcomere is constituted by seven major proteins and several minor ones organized into thin and thick filaments. The thin filaments, anchored at the Z lines, are formed by a double helix of polymerized sarcomeric actin molecules. In the major groove of this double helix is located a continuous head-to-tail coiled coil of tropomyosin (TM)' dimers. Every TM dimer interacts with seven actins and is associated with a troponin (Tn) complex. Each complex is composed of one molecule of each of the three Tns: T, C, and I. This TM-Tn complex is responsible for the calcium sensitivity ofthe contractile apparatus. It regulates the interaction between the heads of the myosin molecule, located in the thick filament, with actin, the main constituent of the thin filament. Although most is known about this inter-action, the precise molecular mechanisms responsible for the biochemical-mechanical transduction have not yet been fully elucidated. The thick filament contains the molecular motor of contraction, the myosin heavy chain (MHC). This is a bifunctional molecule that exists in a dimeric form. The two functional domains are constituted by the rod portion and the head. The rod is constituted by the carboxyl-terminal half of the molecule and is a regular coiled coil a-helix responsible for the assembly of myosin into an organized antiparallel thick filament with heads regularly spaced every 14.3 A at both ends with a bare zone in the middle. The rod carries the load during contraction, and due to its antiparallel organization makes possible the shortening of the sarcomere by pulling together two thin filaments pointing in opposite orientation and attached to two neighboring Z lines. During the contraction cycle the head of MHC, constituted by the amino-terminal half of the molecule, interacts directly with the actin molecules in the thin filament and carries the ATPase activity required to produce the physical translocation needed for fiber shortening. The ATPase activity of MHC is modulated by two smaller protein subunits bound to each MHC head, the alkali and essential myosin light chains (MLC) . As originally pointed out by Barany (3) , there is a direct correlation between the unloaded maximum velocity of shortening of a muscle fiber and the actin-activated ATPase activity of its MHC. Although there are some apparent exceptions to this rule, fibers with a high ATPase activity MHC shorten faster than the ones with a lower enzymatic activity (4, 5) . Interestingly, there is an inverse correlation between ATPase activity of the MHC in a fiber and the energetic cost to perform a given workload (4-6). The faster the fiber, the higher the energetic cost to produce the same amount of work. It is clear, therefore, that the type of MHC present in the sarcomeres is physiologically significant and has a profound effect on the contractile properties of the myocardium.
In addition to the seven major proteins mentioned above, the sarcomere contains a number of proteins, such as a-actinin, C protein, titin, nebulin (7, 8) , etc., that are present in lower amounts and are thought to play an important role either in its organization or modulation of function. However, with the exception of a-actinin, which is the main constituent of the Z line and serves to anchor the actin filament (7) , the precise physiological function of these minor components of the sarcomere remains to be elucidated.
Although the intrinsic properties of the sarcomere are the main determinants of the contractile state, a number of other molecules such as adrenergic receptors (9) , ion channels (10), Na,K ATPase, sarcolemmal and sarcoplasmic calcium pump, sarcoplasmic calcium release channel (11) (12) (13) (14, 15) . In contrast, increasing numbers ofgenes in organisms ranging from insects to human, including their DNA and RNA viruses, are known to be alternatively spliced.
Alternative pre-mRNA splicing is particularly prevalent in striated muscle tissues, including the myocardium. Among the contractile protein genes, this mode of gene regulation has been documented for a-and f3-TM, TnT, and the MLCs, in addition to a number of other genes (reviewed in references 16 and 17). Furthermore, the major constituents of the thick filaments (MHCs and MLCs) and thin filaments (actin, TMs, and Tns [C, T, and I]) of mammalian sarcomeres are each encoded by a multigene family of moderate size ranging from four to eight members (2, 8, 18 ). The expression of each member of these multigene families is regulated at the transcriptional level in a tissue-specific and developmentally regulated manner. The different isoforms of sarcomeric contractile proteins, generated either through the transcription of different genes or from the same gene by alternative pre-mRNA splicing, are able to substitute for each other and to assemble combinatorially when present in the same cell. The restricted combinatorial use of the different members of these multigene families allows for the generation of a moderate number of qualitatively different sarcomere types that, at least in some cases, exhibit significantly different physiological characteristics (8, 9, 18, 19 (23, 24) . Therefore, although the contractile proteins are assembled in the sarcomere in very precise stoichiometric amounts, their regulation is by necessity complex, since it involved multiple genes that are located in different regions of the genome that, with very few exceptions, do not seem to have common regulatory sequences.
Some of the contractile protein isoforms expressed in the myocardium are shared with the skeletal muscle, while others are expressed exclusively in the myocardium (2, 8, 18 ; Table I) ological basis for the selective advantage that has produced this isoform distribution is not apparent from our present understanding of contractility, two main general trends are obvious. In general, the myocardium genes are more likely to be shared with slow than fast skeletal muscle. Embryonic and fetal isoforms are shared more often with striated muscle than their adult counterparts.
Since the MHC isoform switches in the myocardium are physiologically more relevant and are better understood at the molecular level, they will be used to illustrate some of the mechanisms involved. The regulatory processes regulating the expression of these genes appear to be of general significance and, in general terms, are likely to apply to isoform switches in the myocardium.
Isoform switches in response to physiological and pathological stimuli
In the cardiac ventricles of most mammalian species, including the human, three myosin isoforms have been identified based on their electrophoretic mobility: VI, V2, and V3 (24, 25) . However, these three myosins are composed of only two distinct types of MHCs, referred to as a and ,3. V 1 and V3 are composed of aa and f3#3 homodimers, respectively, while V2
is an ad heterodimer. These two myosins are produced by two different genes that are closely linked (21, 22) and are located on chromosomes 14 and 3 in mouse and human, respectively (22) .
As for all muscle types, the myosin composition of the myocardium is of physiological importance, since the relative distribution of a-and f3-MHC is directly correlated with the contractile properties of the heart. The a-MHC, which has high Ca2' and actin-activated ATPase activity (25, 26) , is associated with an increased shortening velocity of the cardiac fibers (26, 27) . In contrast, the fl-MHC, which has lower ATPase activity (25, 26) , is associated with slower shortening velocity (26, 27) . It is, therefore, interesting that the ratio of these two different cardiac isoforms is developmentally regulated. In the ventricles of all mammalian species studied so far f3-MHC is the most abundant isoform in utero until late fetal life (28) (29) (30) . In small mammals, such as rat and mouse, a-MHC increases immediately before birth and becomes the predominant form throughout perinatal and adult life (28, 29 ). In contrast, in large mammals such as man a-MHC is only transiently predominant shortly after birth, with (-MHC becoming the most abundant isoform in the adult (28, 30) . The situation is different in the atria where a-MHC is the predominant isoform throughout life in both small and large species (2, 29, 30) . In addition, in all species studied, including man, the distribution of the cardiac MHC isoforms changes in response to certain pathological and experimental conditions such as work overload (27, (31) (32) (33) (34) , diabetes (35) , gonadectomy (36) , and, more importantly, changes in thyroid hormone levels (24, 26, 29, (37) (38) (39) . These changes are regulated at the level of transcription of the respective genes, since there is a direct correlation between the levels of a-and f3-MHC and the corresponding mRNAs (29, 39) and between these and the rate of transcription (40) .
It is clear now that thyroid hormone plays a fundamental role in the regulation ofthe MHC phenotype both in the myocardium and in skeletal muscle (39). At least in mammals, all the genes of the striated MHC multigene family are, without exception, responsive to thyroid hormone. Surprisingly, how-1696 B. Nadal-Ginard and V. Mahdavi ever, whether the hormone induces or represses the expression of a given MHC depends on the gene itself and the muscle where it is expressed. The same gene can be induced by the hormone in one muscle and repressed in another (39), indicating that the regulation of this gene family by thyroid hormone is likely to be more complex than described so far for a variety of steroid hormones (41) . In the ventricular myocardium there is a precise correlation between the levels of circulating thyroid hormone and the relative levels of a-and f3-MHC (29) . The expression of a-MHC is dependent on the presence of thyroid hormone. In its absence the a-MHC gene is not transcribed. The converse is true for f3-MHC. The expression of this gene is repressed by thyroid hormone and it is induced in hypothyroid states (29, 39). The induction of a-MHC at the time ofbirth is directly correlated with the surge in the circulating thyroid hormone that occurs at this time (29). This effect of thyroid hormone on cardiac MHC expression can be directly demonstrated in experimental animals by manipulating their thyroid state. After surgical or chemical (5-thiouracil) thyroidectomy, the expression of a-MHC is completely suppressed and only f3-MHC is expressed in the myocardium. Replacement therapy restores the normal phenotype (29, 39). On the other hand, hyperthyroid states repress the expression of the fl-MHC gene at both the mRNA and protein levels and produces a myocardium constituted exclusively by a-MHC (29, 39). That these results are not indirect and are not produced by changes in metabolic state, circulating catecholamines, innervation, etc., due to the general effects of changes in thyroid hormone status, is demonstrated by the fact that they can be reproduced in isolated tissue slices and cells in culture (42) .
The molecular mechanism of thyroid hormone action has been elucidated, at least in part, by the demonstration that the c-erb protooncogenes are the nuclear receptors for this hormone (43) (44) (45) (46) . At least two genes with well-defined tissue-specific expression encode this receptor (43) (44) (45) , and each one can generate several different isoforms by alternative splicing (45, 46) . The functional properties of some of these alternatively spliced isoforms are very different and some have lost their ability to bind T3 (46) . It has been recently proposed that some of these isoforms that are impaired in their ability to bind ligand might function as antioncogenes and/or anti-receptor molecules (47, 48) . This is because of their ability to compete for DNA binding sites, but due to their absence ofligand binding are unable to stimulate transcription (46) (47) (48) . Yet, whether this is a general phenomenon remains to be demonstrated. The functional T3 receptors are hormone-dependent transcriptional factors that exercise their effect through binding to a thyroid hormone-responsive element (TRE) in the responsive gene (46, 48, 49) . The TRE for the human and rat a-MHC genes has been determined by a combination of deletion mapping, site-directed mutagenesis, and in vitro and in vivo binding assays (42, 46, 50) . The two genes have a TRE with identical sequence and both are able to confer thyroid hormone sensitivity to heterologous genes (42, 46, 50 (53) . This response is characterized by the reexpression of the protein isoforms normally expressed in fetal life, but that are normally suppressed in adulthood. To the best of our knowledge this phenomenon has been demonstrated for all the gene phenotypes analyzed so far, including other contractile proteins such as skeletal a-actin (53, 54) , MLC 1 (55), and :-TM (53); membrane proteins like the Na,K ATPase (the cardiac glycoside receptor) (56) ; secreted molecules such as atrial natriuretic factor (ANF) (53) ; and those involved in ATP regeneration such as creatine kinase (57) . With the exception of ANF, all the above examples represent the reexpression of an isoform normally expressed only during fetal and early postnatal life that is later replaced by the corresponding adult isoform. ANF expression in the ventricles is normally suppressed after birth and is not replaced by another isoform. Its expression, however, is rapidly reinduced in response to the hypertrophic stimulus.
From the above observations it is clear, therefore, that myocardial hypertrophy is not only a quantitative phenomenon that results in an increase in cardiac mass, but more importantly, results in a significant qualitative change in important constituents of the myocardium. In general, these changes produce a muscle that has many of the biochemical characteristics of the fetal myocardium.
What is the stimulus for this dramatic and concerted change in myocardial gene expression in response to work overload? A potential candidate is thyroid hormone itself. However, as already indicated above, no changes in thyroid hormone levels are detected in these animals. Furthermore, if thyroid hormone were responsible it should be possible to reestablish the normal phenotype in response to thyroid hormone therapy. Yet this is not the case. Thyroid hormone can overcome the effect of pressure overload on MHC gene expression, but has no effect on the other phenotypic changes (51, 53). Administration of high doses of T3 in the hypertrophic animals produces a rapid deinduction of the 0-MHC gene with the concomitant induction of the a-gene, despite the fact that these animals have a higher degree of hypertrophy than those with simple hemodynamic overload (51, 53). None of the changes in the expression of other genes are affected by the hormone. These results give further support to the contention that the changes induced by hemodynamic overload are not secondary to thyroid hormone changes. However, in the case of the MHC genes T3 has a dominant effect and can overcome the regulatory mechanisms induced by the hypotrophic stimulus. This behavior highlights the complex interplay that exists between hemodynamic and hormonal stimuli in myocardial gene expression.
It is noteworthy that in the aortic coarctation animal model system, increased afterload is not the only consequence of the manipulation. It might produce a rise in circulating catecholamine levels and/or activation of the renin-angiotensin system secondary to decreased renal blood flow. NE (58, 59 ) and possibly angiotensin II could, in principle, directly stimulate myocardial cell hypertrophy independently of the hemodynamic effects. The effect of NE on cardiac cell growth in culture has been shown to be mediated by stimulation ofthe a -adrenergic receptor (58) , which couples the hydrolysis of membrane phosphatidylinositol followed by the release of IP3 (60) and activation of protein kinase C (61). Furthermore, phorbol esters, direct activators of protein kinase C, can produce hypertrophy and isoform switches when administered to cultured neonatal cardiac cells (62) . However, the fact that the atria and right ventricles of animals with aortic coarctation do not exhibit the isoform transitions described above strongly suggests that these humoral mechanisms do not play an important role, if they are involved at all, in the processes described here.
Work overload and stretch produce the rapid expression of a set ofprotooncogenes involved in normal cell growth
The cardiac response to normal growth requirements, as well as to work overload, is dependent on the developmental state of the organ. During fetal and early postnatal life the demand for an increased cardiac mass are fulfilled mainly by an increase in the number of myocytes (hyperplasia). However, soon after birth cardiac myocytes lose their ability to divide (1) . Later in life, demand for increased mass is fulfilled exclusively through an increase in the size of a fixed number of preexisting myocytes. The molecular mechanisms responsible for the loss of replicative ability (terminal differentiation) remain completely unknown. Genes involved in determining the myogenic lineage and terminal differentiation in skeletal muscle, such as MyoD (63) , myogenin (64) , and Mif5 (65) Not surprisingly, therefore, c-fos and c-myc mRNAs begin to accumulate within 1 h after the increase in afterload, reach high levels within 3 h, and return to the basal levels in < 24 h. Similarly, the mRNA for one of the major stress proteins, HSP 70, is also increased within 30 min of increasing aortic pressure (53) . Thus, similar to the mitogenic response of a variety of cell types, induction of the cellular protooncogenes and major stress protein genes reflect early changes occurring in the nuclei of myocardial cells in response to acute pressure overload and appear to play an important role in mediating the hypertrophic response. Recently it has been demonstrated that several growth factors, including transforming growth factors ,B and basic fibroblast growth factor, applied to cardiocytes in culture induce a pattern of contractile protein and protooncogene expression that is very similar to the one produced by work overload in the intact heart (69). These results demonstrate that the lack of mitogenic response by the cardiac myocytes is not due to a loss of receptors for growth factors. They also give further support to the hypothesis that work overload affects gene expression through mechanisms similar to or shared by the growth factor receptors. The inability of the cardiocytes to mount a full mitogenic response in response to work overload or growth factors remains an important challenge that also applies to all other terminally differentiated cells, such as neuron and certain epithelial cells. On one hand, these cells could have irreversibly lost the expression of some of the genes required to traverse the cell cycle. In that case it should be impossible for them to reenter the cell cycle in response to any stimulus. On the other hand, as part of the terminally differentiated program they could induce an inhibitor of the cell cycle. In that case, repression or neutralization of the inhibitor should enable the cells to cycle again. Recently, recessive cellular oncogenes with many of the properties required for this role have been described. One of them, the product of the retinoblastoma gene, has been shown to belong to this class. The activity of this gene product is neutralized by certain viral oncogenes, SV40 T antigen (70) and adenovirus E IA (71) . Based on the finding that SV40 T antigen is able to reinduce the ability to cycle to terminally differentiated myotubes (72) , it has been possible to reinduce the cell cycle in terminally differentiated cardiocytes and to create cell lines that express many of the differentiated characteristics (Thompson, R., B. Nadal-Ginard, and V. Mahdavi, unpublished observations). These results suggest the presence of inhibitors in the differentiated cardiocytes. Identification of the molecule(s) involved could provide the tool required to induce cardiac muscle regeneration.
In various models of cardiac hypertrophy, systolic and diastolic wall stress have both been implicated as major determinants of the degree and pattern of hypertrophy during pressure and volume overload (73) . In addition, studies using isolated heart preparations have demonstrated that increased wall tension alone can directly stimulate protein synthesis (1, 2) . Although the precise molecular mechanisms by which wall stress is communicated to the myocyte nucleus remain to be elucidated, the recently discovered stretch-sensitive ion channels (74) provide a likely candidate for the sensor mechanism. These channels could provide a very sensitive measure of wall stress. The ionic changes produced by their opening or closing could trigger a second messenger cascade (perhaps involving IP3) that results in the changes in gene expression described above. The recent demonstration that stretch of isolated car-diocytes in culture induces the changes of contractile gene and protooncogene expression described for work overload and growth factors is in agreement with this hypothesis.
In physiological terms, the reexpression of the fetal isogenes might be a beneficial adaptation to hemodynamic overload. As a consequence of the changes induced in the thin and thick filaments during cardiac hypertrophy, sarcomeres with significantly different functional properties are produced. For the myocardium, the fetal isoform of MHC has been shown to be bioenergetically more efficient than that of the adult. Moreover, because ANF has potent natriuretic, diuretic, and vasodilatory effects, the marked induction of this molecule in the ventricle in response to increased blood pressure might be interpreted as an adaptational response to reduce hemodynamic load imposed on the ventricle.
In conclusion, the results summarized here demonstrate that the myocardium is a biochemically very plastic tissue that is amenable to cellular and molecular dissection and can serve as a good experimental model to address some important questions that are relevant to the cardiovascular system but are also of general biological significance. In addition, it is clear that cardiac hypertrophy is not a simple quantitative increase in ventricular mass, but a qualitatively different and heterogeneous process that is highly influenced by the nature of the hypertrophic stimulus and the developmental stage of the myocardium. Induction of cellular protooncogenes that play a role in cell growth in the very early stages of work overload hypertrophy mimics the mitogenic response to growth factors by a variety of cells. The quantitative and qualitative changes in the expression of contractile and regulatory genes that occurs later, most likely represent only a small sample of the changes produced in the myocardium in response to the hypertrophic stimuli. The fact that each fetal gene examined so far is reexpressed in response to pressure overload hypertrophy suggests that reinduction of the fetal program might be a general adaptive process to hemodynamic stress. Further work is needed, however, to elucidate the precise mechanisms by which the hemodynamic and/or mechanic stimuli are converted into biochemical signals that lead to quantitative as well as qualitative changes in gene expression. A better understanding of the genes involved in converting precursor mesenchymal cells into the cardiogenic pathway, the cell-specific transcriptional factors responsible for the expression of the cardiac specific genes, and the genes involved in blocking these cells in the terminally differentiated phenotype is also required. This information is essential to be able to manipulate the process of cardiac hypertrophy and changes of contractile state to physiological advantage.
